Format

Send to

Choose Destination
EMBO Mol Med. 2014 Jul;6(7):851-64. doi: 10.15252/emmm.201100899.

Development of microRNA therapeutics is coming of age.

Author information

1
Hubrecht Institute, KNAW and University Medical Center, Utrecht, The Netherlands e.vanrooij@hubrecht.eu sk@bio.aau.dk.
2
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark Department of Haematology, Aalborg University Hospital, Aalborg, Denmark e.vanrooij@hubrecht.eu sk@bio.aau.dk.

Abstract

MicroRNAs (miRNAs) play key regulatory roles in diverse biological processes and are frequently dysregulated in human diseases. Thus, miRNAs have emerged as a class of promising targets for therapeutic intervention. Here, we describe the current strategies for therapeutic modulation of miRNAs and provide an update on the development of miRNA-based therapeutics for the treatment of cancer, cardiovascular disease and hepatitis C virus (HCV) infection.

KEYWORDS:

antimiR; miRNA; mimic; therapeutics

PMID:
24935956
PMCID:
PMC4119351
DOI:
10.15252/emmm.201100899
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center